Compare Revvity Inc (RVTY) vs Snap Inc (SNAP) Price & Performance

RVTY trades at $116.10, up 0.07% on the day, with a bullish technical signal and strong earnings beats in recent quarters. The company reported Q2 2026 EPS of $1.41, surpassing the $1.21 estimate, and raised its full-year outlook due to robust diagnostics demand. Revenue remains steady around $2.9 billion, with a net income margin of 8.16%. Analyst consensus is a Buy with a $120.50 price target, and recent news highlights product launches like the SuperFlex prenatal system and high-throughput TB testing platform.

The outlook for RVTY is positive, supported by earnings momentum and strategic innovations, but investors face risks from high valuation multiples and competitive pressures in the healthcare sector. The stock's proximity to its consensus target suggests limited near-term upside, requiring careful monitoring of execution against raised guidance.

Snap Inc. (SNAP) trades at $5.285, down 1.03% over 24 hours, near its analyst low target of $5.25. The stock shows a bullish technical signal with strong moving average support, though RSI levels indicate overbought conditions. Fundamentally, revenue grew to $5.93B in 2025 with a narrowing net loss of -$460M, while Q2 2026 earnings beat expectations with 19% revenue growth. Cash flow from operations improved to $656M in 2025, signaling operational strength amid persistent losses.

Outlook remains cautious with a consensus price target of $7.02, implying 33% upside, but risks include high debt, negative profitability, and competitive pressures. Institutional sentiment is mixed with 38% buy ratings, yet insider selling and a recent downgrade to strong sell highlight volatility. Investment opportunity hinges on sustained ad revenue growth and path to profitability, balanced against execution risks in a challenging digital ad market.